Enveric Biosciences, Inc.

Enveric Biosciences, Inc. (ticker: ENVB) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of ENVB's SEC filings surfaces 8 active risk signals, including 5 late-filing signals, 2 auditor-change signals, and 1 delisting/deregistration signal. ENVB reported $26.34M in revenue and $12.10M for the period ending 2020-09-30, with operating cash flow of -$8.14M. Cash and equivalents stood at $4.68M (up 108.7% year-over-year). Total assets of $5.10M exceed total liabilities of $4.00M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

ENVB Cash Runway

Months-of-runway analysis for ENVB, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on ENVB

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.